Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Theophylline Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A known ✓ | P27815 | 9/20 | 0.81 |
| ▸ | PDE4B known ✓ | Q07343 | 9/20 | 0.81 |
| ▸ | PDE4C known ✓ | Q08493 | 9/20 | 0.81 |
| ▸ | PDE4D known ✓ | Q08499 | 9/20 | 0.81 |
| ▸ | ADORA2A known ✓ | P29274 | 8/20 | 0.81 |
| ▸ | ADORA2B known ✓ | P29275 | 8/20 | 0.81 |
| ▸ | ADORA3 known ✓ | P0DMS8 | 4/20 | 0.81 |
| ▸ | ADORA1 known ✓ | P30542 | 2/20 | 0.81 |
| ▸ | PDE3B known ✓ | Q13370 | 1/20 | 0.58 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.84 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.81 |
| ▸ | ALPL | P05186 | 1/20 | 0.81 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.81 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.81 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.81 |
| ▸ | CFTR | P13569 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Theophylline Anhydrous SCHEMBL393183 | 1.00 | CYP1A2 (1.00) | CYP1A2LMNAMAPTATAD2PDE4A | |
| Theophylline Anhydrous SCHEMBL5037 | 1.00 | CYP1A2 (1.00) | CYP1A2LMNAMAPTATAD2PDE4A | |
| Theophylline Anhydrous SCHEMBL5181434 | 1.00 | CYP1A2 (1.00) | CYP1A2LMNAMAPTATAD2PDE4A | |
| Theophylline Anhydrous SCHEMBL19987964 | 0.98 | CYP1A2 (0.97) | CYP1A2LMNAMAPTATAD2PDE4A | |
| Theophylline Anhydrous SCHEMBL9792548 | 0.98 | CYP1A2 (0.97) | CYP1A2LMNAMAPTATAD2PDE4A | |
| Theophylline Anhydrous SCHEMBL11187438 | 0.98 | CYP1A2 (0.97) | CYP1A2LMNAMAPTATAD2PDE4A | |
| Theophylline Anhydrous SCHEMBL7546366 | 0.98 | CYP1A2 (0.97) | CYP1A2LMNAMAPTATAD2PDE4A | |
| Theophylline Anhydrous SCHEMBL1022085 | 0.98 | CYP1A2 (0.97) | CYP1A2LMNAMAPTATAD2PDE4A | |
| Theophylline Anhydrous SCHEMBL8719730 | 0.97 | CYP1A2 (0.94) | CYP1A2LMNAMAPTATAD2PDE4A | |
| Theophylline Anhydrous SCHEMBL28274666 | 0.95 | CYP1A2 (0.91) | CYP1A2LMNAMAPTATAD2PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8058243-B2 | Method for treating a brain cancer with ifenprodil | HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) | 2011-11-15 | — | — | US | disclosed |
| US-20090076019-A1 | METHODS FOR TREATING NEUROLOGICAL DISORDERS OR DAMAGE | MOUNT SINAI HOSPITAL (CA) | 2009-03-19 | — | — | US | disclosed |